THE EARLY DETECTION OF
CANCER SAVES LIVES

A SIMPLE SCREENING TEST FOR CANCER

This paper provides a review of the history, science and use of this major medical advancement

The paper, “A Simple Screening Test for Cancer”, was published April 2021, in the medical journal- Advances in Cancer Research and Clinical Imaging.

To read the paper please click on the link below:

A HUGE VOID IN MEDICINE IS A LACK OF CANCER SCREENING TESTS

If judged on how many people can be saved, this is one of the biggest medical advances in decades

With 600,000 annual deaths, cancer is a leading cause of mortality in the US, 2nd only to heart disease, which claims 650,000 annually. Early-stage cancer patients typically have no symptoms and so often they are unaware that a cancer already exists and maybe spreading.

Finding cancer after it has already spread dramatically decreases the chance of survival. For example, estimates are that stage 1 colon cancer patients have a 95% chance to live 5 years, whereas those with stage 4 colon cancer, which means that the cancer has already metastasized or spread to other organs, have less than a 10% chance of living 5 years.

A Long Overdue Solution

A challenge with current imaging screening tests such as CTs, mammograms and x-rays etc., is that tumors have to be a certain size to be found. As a result, a number of early-stage tumors are missed simply because they are small.

We have developed the 1st point-of-care cancer screening tests. The tests identify an altered sugar molecule that is only produced by precancerous tissues and cancers.

Identifying patients at risk at the earliest stages of cancer, even tissue at risk of becoming cancerous is the most significant benefit of this technology. Thousands of patients in multiple published clinical trials have typically shown an accuracy of 80 to 95%.

Note: Screening tests are not diagnostic tests. Rather, screening tests are used to alert doctors that asymptomatic patients are at an increased risk, and that further evaluation and testing may be needed. An example of a well-known screening test is the recent temperature checks taking place at airports to screen for Covid.

The Science Behind the Product:

For a decade, as transplant physicians harvested organs, Dr. Shamsuddin, who was a pathologist with a specialty in colon cancer, collected healthy intestinal tissue for research. He compared this truly healthy tissue from organ donors, with similar looking and supposedly “healthy” tissue, found in other locations in the colon of colon cancer patients.

Once the tissue was stained, under the microscope, he noticed a very slight color variance between the intestinal mucus from the organ donors and those with cancer. Plus, the mucus from tumors was the same color as supposedly “healthy” intestinal tissue samples taken from various locations in the colon of these cancer patients.

1/2 OF DEATHS ARE FROM
LUNG-COLON-BREAST-PROSTATE-UTERINE

1 IN 4 ARE DIAGNOSED WITH THESE CANCERS- WE’RE ALL AT RISK!

Uterine 4+ Million will be Diagnosed in US - 1 in 40
women

12,940 estimated deaths in the US in 2021

There is no screening test for uterine cancer.

There is a critical need for a safe, accurate early-stage uterine cancer screening test.

Lung 20+ Million will be Diagnosed in US - 1 in 16
people

20% or 4 million+ of diagnosed are nonsmokers, 25000+ of the 2021 deaths are non-smokers

131,880 estimated deaths in the US in 2021, Smokers and non-smokers, we’re all at risk!

There is no standard screening test for lung cancer! Chest CT exams are costly and emit a lot of radiation.

Breast 20+ Million will be Diagnosed in US - 1 in 8
women

43,600 estimated deaths in the US in 2021

Physical breast exams and mammograms may miss up to 40% of early-stage breast tumors.

There is a critical need for a safe, accurate early-stage breast cancer screening test.

Colon 15+ Million will be Diagnosed in US - 1 in 22
people

52,980 estimated deaths in the US in 2021

Standard screening for blood in the stool can miss early-stage tumors, as they may not yet be bleeding. New blood & DNA screening is more accurate, however much more expensive.

No longer will patients have to collect their stool and send it to the lab. This screening test can be completed in 15 minutes by the physician and/or office staff.

Prostate 18+ Million will be Diagnosed in US - 1 in 9
men

34,130 estimated deaths in the US in 2021

Current screening test is the PSA Test, which has limited predictive value, as the PSA test does not effectively differentiate between a benign enlarged prostate (BPH) versus a cancerous prostate.

Many senior men worry about this, as they are unsure if frequent or nighttime urination is due to cancer or an enlarged prostate.

EARLY DETECTION, OFTEN THE DIFFERENCE BETWEEN LIVING & DYING